Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease (vol 363, 114370, 2023)

被引:0
|
作者
Corsi, Sara [1 ]
Scheggi, Simona [2 ]
Pardu, Alessandra [1 ]
Braccagni, Giulia [2 ]
Caruso, Donatella [3 ]
Cioffi, Lucia [2 ]
Diviccaro, Silvia [3 ,4 ]
Gentile, Mauro [1 ]
Fanni, Silvia [1 ]
Stancampiano, Roberto [1 ]
Gambarana, Carla [2 ]
Melcangi, Roberto Cosimo [3 ]
Frau, Roberto [1 ,5 ]
Carta, Manolo [1 ]
机构
[1] Univ Cagliari, Dept Biomed Sci, Cagliari, CA, Italy
[2] Univ Siena, Dept Mol & Dev Med, Siena, SI, Italy
[3] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, MI, Italy
[4] Lund Univ, Basal Gangl Pathophysiol Unit, Dept Expt Med Sci, Lund, Sweden
[5] Univ Cagliari, Guy Everett Lab, Dept Biomed Sci, Cagliari, Italy
关键词
D O I
10.1016/j.expneurol.2023.114640
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
引用
收藏
页数:1
相关论文
共 50 条
  • [21] The Kinase Fyn As a Novel Intermediate in l-DOPA-Induced Dyskinesia in Parkinson’s Disease
    Sara Sanz-Blasco
    Melina P. Bordone
    Ana Damianich
    Gimena Gomez
    M. Alejandra Bernardi
    Luciana Isaja
    Irene R. Taravini
    Diane P. Hanger
    M. Elena Avale
    Oscar S. Gershanik
    Juan E. Ferrario
    Molecular Neurobiology, 2018, 55 : 5125 - 5136
  • [22] A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia
    Conti, Melissa M.
    Chambers, Nicole
    Bishop, Christopher
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2018, 92 : 67 - 82
  • [23] CSF catecholamine and kynurenine metabolites in Parkinson's disease and L-DOPA-induced dyskinesia
    Andersen, A. D.
    Havelund, J.
    Binzer, M.
    Blaabjerg, M.
    Kamal, A.
    Thagesen, H.
    Kjaer, T. W.
    Frgeman, N. J. K.
    Heegaard, N. H. H.
    Stenager, E.
    Gramsbergen, J. B.
    JOURNAL OF NEUROCHEMISTRY, 2017, 142 : 107 - 107
  • [24] The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease
    Sanz-Blasco, Sara
    Bordone, Melina P.
    Damianich, Ana
    Gomez, Gimena
    Alejandra Bernardi, M.
    Isaja, Luciana
    Taravini, Irene R.
    Hanger, Diane P.
    Elena Avale, M.
    Gershanik, Oscar S.
    Ferrario, Juan E.
    MOLECULAR NEUROBIOLOGY, 2018, 55 (06) : 5125 - 5136
  • [25] l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
    Del-Bel, Elaine
    Bortolanza, Mariza
    Dos-Santos-Pereira, Mauricio
    Bariotto, Keila
    Raisman-Vozari, Rita
    SYNAPSE, 2016, 70 (12) : 479 - 500
  • [26] The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia
    Gutierrez-Valdez, Ana L.
    Garcia-Ruiz, Ricardo
    Anaya-Martinez, Veronica
    Torres-Esquivel, Carmen
    Espinosa-Villanueva, Jesus
    Reynoso-Erazo, Leonardo
    Tron-Alvarez, Rocio
    Aley-Medina, Patricia
    Sanchez-Betancourt, Javier
    Montiel-Flores, Enrique
    Avila-Costa, Maria R.
    BEHAVIOURAL PHARMACOLOGY, 2013, 24 (08): : 640 - 652
  • [27] Which is a more important risk factor for L-DOPA-induced dyskinesia, age at onset of Parkinson's disease or age at L-DOPA treatment for Parkinson's disease?
    Kimura, Tamaki
    Tomiyama, Masahiko
    Arai, Akira
    Suzuki, Chieko
    Shouji, Mikio
    NEUROSCIENCE RESEARCH, 2008, 61 : S203 - S203
  • [28] 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model
    Tronci, Elisabetta
    Lisci, Carlo
    Stancampiano, Roberto
    Fidalgo, Camino
    Collu, Maria
    Devoto, Paola
    Carta, Manolo
    NEUROBIOLOGY OF DISEASE, 2013, 60 : 108 - 114
  • [29] Behavioral effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice
    Sano, Hiromi
    Nambu, Atsushi
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [30] Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson’s Disease and L-DOPA-Induced Dyskinesia
    D. P. Ferrari
    M. Bortolanza
    E. A. Del Bel
    Neurotoxicity Research, 2021, 39 : 705 - 719